269 related articles for article (PubMed ID: 18927431)
21. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
[TBL] [Abstract][Full Text] [Related]
22. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
[TBL] [Abstract][Full Text] [Related]
23. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
25. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
[TBL] [Abstract][Full Text] [Related]
26. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract][Full Text] [Related]
27. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
28. Acetylation inactivates the transcriptional repressor BCL6.
Bereshchenko OR; Gu W; Dalla-Favera R
Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
[TBL] [Abstract][Full Text] [Related]
29. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
30. GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.
Pearce AC; Bamford MJ; Barber R; Bridges A; Convery MA; Demetriou C; Evans S; Gobbetti T; Hirst DJ; Holmes DS; Hutchinson JP; Jayne S; Lezina L; McCabe MT; Messenger C; Morley J; Musso MC; Scott-Stevens P; Manso AS; Schofield J; Slocombe T; Somers D; Walker AL; Wyce A; Zhang XP; Wagner SD
J Biol Chem; 2021 Aug; 297(2):100928. PubMed ID: 34274316
[TBL] [Abstract][Full Text] [Related]
31. The role of BCL6 in lymphomas and routes to therapy.
Wagner SD; Ahearne M; Ko Ferrigno P
Br J Haematol; 2011 Jan; 152(1):3-12. PubMed ID: 21083654
[TBL] [Abstract][Full Text] [Related]
32. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
34. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.
Baron BW; Anastasi J; Thirman MJ; Furukawa Y; Fears S; Kim DC; Simone F; Birkenbach M; Montag A; Sadhu A; Zeleznik-Le N; McKeithan TW
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2860-5. PubMed ID: 11854457
[TBL] [Abstract][Full Text] [Related]
35. Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.
Beck D; Zobel J; Barber R; Evans S; Lezina L; Allchin RL; Blades M; Elliott R; Lord CJ; Ashworth A; Porter AC; Wagner SD
J Biol Chem; 2016 Aug; 291(32):16686-98. PubMed ID: 27268052
[TBL] [Abstract][Full Text] [Related]
36. The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation.
Jaye DL; Iqbal J; Fujita N; Geigerman CM; Li S; Karanam S; Fu K; Weisenburger DD; Chan WC; Moreno CS; Wade PA
J Pathol; 2007 Sep; 213(1):106-15. PubMed ID: 17573669
[TBL] [Abstract][Full Text] [Related]
37. Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT).
Shibata H; Nawaz Z; Tsai SY; O'Malley BW; Tsai MJ
Mol Endocrinol; 1997 Jun; 11(6):714-24. PubMed ID: 9171235
[TBL] [Abstract][Full Text] [Related]
38. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
Guo W; Xing Y; Zhang Q; Xie J; Huang D; Gu H; He P; Zhou M; Xu S; Pang X; Liu M; Yi Z; Chen Y
J Med Chem; 2020 Jan; 63(2):676-695. PubMed ID: 31895575
[TBL] [Abstract][Full Text] [Related]
40. Bcl6 middle domain repressor function is required for T follicular helper cell differentiation and utilizes the corepressor MTA3.
Nance JP; Bélanger S; Johnston RJ; Hu JK; Takemori T; Crotty S
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13324-9. PubMed ID: 26460037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
